Exelixis-Phase 2 Study of Zanzalintinib in Recurrent or Progressive Meningioma (XL092-201)

Exelixis-Phase 2 Study of Zanzalintinib in Recurrent or Progressive Meningioma (XL092-201)

Es posible que algunos contenidos no estén disponibles en español.

Study Details

Full Title

A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (XL092-201)

Principal Investigator

Katherine
Peters

Protocol Number

PRO00119908

NCT ID

NCT07428616

Phase

II

Enrollment Status

Open to Enrollment
ClinicalTrials.gov